Canterbury DHB



MDS is classified according to the WHO classification, an updated version was published in 2016. Use the updated version to define the specific subtype of MDS and send this information to the New Zealand Cancer Registry (NZCR) for all new diagnoses. See Diagnosis for the diagnostic criteria.

Changes in the 2016 guidelines include:

The dysplastic lineage ("MDS with single lineage dysplasia" or "MDS with multilineage dysplasia") is now described, rather than the cytopenic lineage ("refractory anaemia" in the 2008 classification).

WHO classification of myeloid neoplasms and acute leukaemia (2016)

Myelodysplastic syndromes (MDS)

Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

About this Canterbury DHB document (4954):

Document Owner:

Emma-Jane McDonald (see Who's Who)

Issue Date:

June 2017

Next Review:

June 2019


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 4954